溶酶体贮积症的分子机制：从发病机制到治疗策略
Molecular Mechanisms in Lysosomal Storage Diseases: From Pathogenesis to Therapeutic Strategies.
作者信息
De Pasquale Valeria, Scarcella Melania, Pavone Luigi Michele
机构信息
Department of Veterinary Medicine and Animal Productions, University of Naples Federico II, Via F. Delpino 1, 80127 Naples, Italy.
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Via S. Pansini 5, 80131 Naples, Italy.
出版信息
Biomedicines. 2022 Apr 17;10(4):922. doi: 10.3390/biomedicines10040922.
Abstract
Lysosomal storage diseases (LSDs) are a group of metabolic diseases caused by inborn mutations of lysosomal enzymes, which lead to lysosome substrate accumulation in various cell types [...].
摘要
溶酶体贮积症（LSDs）是一组由溶酶体酶的先天性突变引起的代谢性疾病，这些突变导致溶酶体底物在各种细胞类型中积累[...]。
相似文献
1
Molecular Mechanisms in Lysosomal Storage Diseases: From Pathogenesis to Therapeutic Strategies.溶酶体贮积症的分子机制：从发病机制到治疗策略
Biomedicines. 2022 Apr 17;10(4):922. doi: 10.3390/biomedicines10040922.
2
Lysosomal exocytosis and lipid storage disorders.溶酶体胞吐作用与脂质贮积病
J Lipid Res. 2014 Jun;55(6):995-1009. doi: 10.1194/jlr.R046896. Epub 2014 Mar 25.
3
Autophagy and Lysosome Storage Disorders.自噬与溶酶体贮积症
Adv Exp Med Biol. 2020;1207:87-102. doi: 10.1007/978-981-15-4272-5_5.
4
Role of induced pluripotent stem cells in lysosomal storage diseases.诱导多能干细胞在溶酶体贮积症中的作用。
Mol Cell Neurosci. 2020 Oct;108:103540. doi: 10.1016/j.mcn.2020.103540. Epub 2020 Aug 21.
5
Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.溶酶体贮积症的酶增强治疗学：现状与展望。
Mol Genet Metab. 2019 Feb;126(2):83-97. doi: 10.1016/j.ymgme.2018.11.011. Epub 2018 Nov 22.
6
Finding pathogenic commonalities between Niemann-Pick type C and other lysosomal storage disorders: Opportunities for shared therapeutic interventions.在尼曼-匹克 C 型和其他溶酶体贮积症之间寻找致病共性：共同治疗干预的机会。
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165875. doi: 10.1016/j.bbadis.2020.165875. Epub 2020 Jun 6.
7
Disease pathogenesis explained by basic science: lysosomal storage diseases as autophagocytic disorders.基础科学解释的疾病发病机制：溶酶体贮积病作为自噬性疾病
Int J Clin Pharmacol Ther. 2009;47 Suppl 1:S34-8. doi: 10.5414/cpp47034.
8
Lysosomal storage diseases.溶酶体贮积症。
Nat Rev Dis Primers. 2018 Oct 1;4(1):27. doi: 10.1038/s41572-018-0025-4.
9
Lysosomal storage disorders: old diseases, present and future challenges.溶酶体贮积症：古老的疾病，当前与未来的挑战
Pediatr Endocrinol Rev. 2013 Nov;11 Suppl 1:59-63.
10
Disruption of morphogenic and growth pathways in lysosomal storage diseases.溶酶体贮积症中形态发生和生长途径的破坏。
WIREs Mech Dis. 2021 Sep;13(5):e1521. doi: 10.1002/wsbm.1521. Epub 2021 Feb 25.
本文引用的文献
1
Surgical Management of Valvular Heart Disease in Mucopolysaccharidoses: A Review of Literature.黏多糖贮积症中瓣膜性心脏病的外科治疗：文献综述
Biomedicines. 2022 Feb 4;10(2):375. doi: 10.3390/biomedicines10020375.
2
Storage of Mutant Human SOD1 in Non-Neural Cells from the Type-1 Amyotrophic Lateral Sclerosis rat Model Correlated with the Lysosomes' Dysfunction.1型肌萎缩侧索硬化大鼠模型非神经细胞中突变型人SOD1的储存与溶酶体功能障碍相关。
Biomedicines. 2021 Aug 24;9(9):1080. doi: 10.3390/biomedicines9091080.
3
Competitive binding of extracellular accumulated heparan sulfate reduces lysosomal storage defects and triggers neuronal differentiation in a model of Mucopolysaccharidosis IIIB.细胞外积累的硫酸乙酰肝素的竞争性结合减少了溶酶体储存缺陷，并在黏多糖贮积症IIIB模型中触发神经元分化。
Biochim Biophys Acta Mol Cell Res. 2021 Oct;1868(11):119113. doi: 10.1016/j.bbamcr.2021.119113. Epub 2021 Jul 28.
4
Artificially Induced Pluripotent Stem Cell-Derived Whole-Brain Organoid for Modelling the Pathophysiology of Metachromatic Leukodystrophy and Drug Repurposing.用于模拟异染性脑白质营养不良病理生理学和药物再利用的人工诱导多能干细胞衍生全脑类器官
Biomedicines. 2021 Apr 20;9(4):440. doi: 10.3390/biomedicines9040440.
5
Murine Models of Lysosomal Storage Diseases Exhibit Differences in Brain Protein Aggregation and Neuroinflammation.溶酶体贮积症的小鼠模型在脑蛋白聚集和神经炎症方面存在差异。
Biomedicines. 2021 Apr 21;9(5):446. doi: 10.3390/biomedicines9050446.
6
Exploiting the Potential of Models in Lysosomal Storage Disorders: Pathological Mechanisms and Drug Discovery.挖掘溶酶体贮积症模型的潜力：病理机制与药物发现
Biomedicines. 2021 Mar 7;9(3):268. doi: 10.3390/biomedicines9030268.
7
The rapidly evolving view of lysosomal storage diseases.溶酶体贮积症的快速演变观点。
EMBO Mol Med. 2021 Feb 5;13(2):e12836. doi: 10.15252/emmm.202012836. Epub 2021 Jan 18.
8
Screening for Fabry Disease in Kidney Transplant Recipients: Experience of a Multidisciplinary Team.肾移植受者中Fabry病的筛查：一个多学科团队的经验
Biomedicines. 2020 Oct 7;8(10):396. doi: 10.3390/biomedicines8100396.
9
Transmissible Endosomal Intoxication: A Balance between Exosomes and Lysosomes at the Basis of Intercellular Amyloid Propagation.可传播的内体中毒：细胞间淀粉样蛋白传播基础上外泌体与溶酶体之间的平衡
Biomedicines. 2020 Aug 4;8(8):272. doi: 10.3390/biomedicines8080272.
10
Targeted Metabolomic Analysis of a Mucopolysaccharidosis IIIB Mouse Model Reveals an Imbalance of Branched-Chain Amino Acid and Fatty Acid Metabolism.靶向代谢组学分析 IIIB 型黏多糖贮积症小鼠模型揭示支链氨基酸和脂肪酸代谢失衡。
Int J Mol Sci. 2020 Jun 12;21(12):4211. doi: 10.3390/ijms21124211.
Zotero 插件